An important drawback in the management of glioblastoma (GBM) patients is the frequent relapse upon surgery and therapy. A likely explanation is that conventional therapies poorly affect a small population of stem-like cancer cells (glioblastoma stem cells, GSCs) that remain capable of repopulating the tumour mass. Indeed, the development of therapeutic strategies able to hit GSCs while reducing the tumour burden has become an important challenge to increase a patient’s survival. The signal transducer and activator of transcription-3 (STAT3) has been reported to play a pivotal role in maintaining the tumour initiating capacity of the GSC population. Therefore, in order to impair the renewal and propagation of the PDGFRβ-expressing GSC population, here we took advantage of the aptamer–siRNA chimera (AsiC), named Gint4.T-STAT3, that we previously have shown to efficiently antagonize STAT3 in subcutaneous PDGFRβ-positive GBM xenografts. We demonstrate that the aptamer conjugate is able to effectively and specifically prevent patient-derived GSC function and expansion. Moreover, because of the therapeutic potential of using miR-10b inhibitors and of the broad expression of the Axl receptor in GBM, we used the GL21.T anti-Axl aptamer as the targeting moiety for anti-miR-10b, showing that, in combination with the STAT3 AsiC, the aptamer–miR-10b antagonist treatment further enhances the inhibition of GSC sphere formation. Our results highlight the potential to use a combined approach with targeted RNA therapeutics to inhibit GBM tumour dissemination and relapse.
We present here the fundamentals of aptamer selection, beginning with the original in vitro systematic evolution of ligands by exponential enrichment (SELEX) protocol, first described in 1990, and culminating in recent advances in aptamer selection methodologies that have fast-tracked the development of aptamers for several research and therapeutic applications. These include advances in chemistries to impart stability and reduce toxicity, methodologies that have enabled the identification of aptamers to more complex targets and novel technologies such as next-generation sequencing (NGS), to fast-track the selection process and to provide a more complete in silico analysis of aptamer sequence families and their functional properties. We have highlighted applications of aptamers as research tools and as unique reagents for diagnostic and therapeutic applications. We have concluded this survey with an overview of those aptamers that have undergone clinical development and/or evaluation and have discussed the applications of this new class of chemically-modified oligonucleotides as potential diagnostics and therapeutics for a variety of clinical indications. We believe that aptamers constitute a research field with great potential for future advances.